Celularity Investor Relations Material

Celularity Inc. is a biotechnology company focused on developing off-the-shelf, placental-derived allogeneic cell therapies for treating cancer, immune, and infectious diseases. The company's core therapeutic products include genetically modified and unmodified natural killer (NK) cells, CAR-T cells, and mesenchymal-like adherent stromal cells. Additionally, Celularity produces placental-derived biomaterials used in various therapeutic applications. It operates through three main segments: Cell Therapy, Degenerative Disease, and BioBanking. The company is headquartered in Florham Park, New Jersey, and its shares are listed on NASDAQ.